Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 [Yahoo! Finance]
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate [Yahoo! Finance]
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader [Yahoo! Finance]
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics (NASDAQ:KYMR) was given a new $133.00 price target on by analysts at Barclays PLC.